0001062993-25-005299.txt : 20250312 0001062993-25-005299.hdr.sgml : 20250312 20250312194738 ACCESSION NUMBER: 0001062993-25-005299 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250310 FILED AS OF DATE: 20250312 DATE AS OF CHANGE: 20250312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NEUPERT PETER M CENTRAL INDEX KEY: 0001237566 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 25733390 MAIL ADDRESS: STREET 1: 13920 SE EASTGATE WAY STREET 2: STE 300 CITY: BELLEVUE STATE: WA ZIP: 98005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2025-03-10 0001478320 Adaptive Biotechnologies Corp ADPT 0001237566 NEUPERT PETER M C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST SEATTLE WA 98109 1 0 0 0 0 Common Stock 2025-03-10 4 M 0 50000 4.07 A 234690 D Common Stock 2025-03-10 4 S 0 10000 7.05 D 224690 D Stock Option (right to buy) 4.07 2025-03-10 4 M 0 50000 0 D 2025-03-31 Common Stock 50000 0 D The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.03 to 7.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option was fully vested and exercisable. /s/ Peter M Neupert by Kyle Piskel, Attorney-in-Fact 2025-03-12